Xeltis is Trialing its Polymer-based Vascular Access
aXess is a self-healing device that allows the patient’s cells to colonize a polymeric matrix which then becomes an access. A U.S. trial has started enrolling patients. The FDA granted Xeltis Breakthrough Device Designation status.
Read the full article » | Posted 03-12-2026
Related Articles
- New Bluetooth-enabled CAPD System Enhanced Patient Satisfaction Posted 03-12-2026
- Emerging Biomarker Research in PD Posted 03-12-2026
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026
- FDA granted 510(k) approval to Outset for Next generation Tablo with Cybersecurity Posted 02-17-2026